Do analysts rate COCP or MCRB?

Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 227.49%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is COCP or MCRB more profitable?

Seres Therapeutics' return on equity of -130.29% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Seres Therapeutics N/A -130.29% -35.35%

Do analysts recommend TCRT or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TCRT or COCP more profitable?

Cocrystal Pharma's return on equity of -150.61% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Cocrystal Pharma N/A -150.61% -97.86%

Do analysts rate MREO or COCP?

Mereo BioPharma Group presently has a consensus price target of $3.25, indicating a potential upside of 976.16%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, equities analysts plainly believe Mereo BioPharma Group is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MREO or COCP more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% Cocrystal Pharma N/A -150.61% -97.86%

Do analysts prefer MGX or COCP?

Metagenomi currently has a consensus price target of $7.00, indicating a potential upside of 481.88%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts plainly believe Metagenomi is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor MGX or COCP?

In the previous week, Metagenomi had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Metagenomi and 1 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.00 beat Metagenomi's score of -0.28 indicating that Cocrystal Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer COCP or SCYX?

SCYNEXIS has a consensus price target of $24.00, suggesting a potential upside of 492.45%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Cocrystal Pharma (COCP) Competitors

$0.94 +0.01 (+0.85%)

As of 03:09 PM Eastern

Compare

COCP vs. MCRB, TCRT, MREO, MGX, and SCYX

Should you buy Cocrystal Pharma stock or one of its competitors? MarketBeat compares Cocrystal Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cocrystal Pharma include Seres Therapeutics (MCRB), Alaunos Therapeutics (TCRT), Mereo BioPharma Group (MREO), Metagenomi (MGX), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry.

How does Cocrystal Pharma compare to Seres Therapeutics?

Cocrystal Pharma (NASDAQ:COCP) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Cocrystal Pharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 227.49%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Seres Therapeutics' return on equity of -130.29% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Seres Therapeutics	N/A	-130.29%	-35.35%

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Seres Therapeutics has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	$225K	57.48	-$8.83M	-$0.73	N/A
Seres Therapeutics	$790K	63.61	$5.70M	-$5.17	N/A

In the previous week, Cocrystal Pharma had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Seres Therapeutics. Cocrystal Pharma's average media sentiment score of 0.00 equaled Seres Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Seres Therapeutics	Neutral

Summary

Seres Therapeutics beats Cocrystal Pharma on 10 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, Cocrystal Pharma had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Cocrystal Pharma	Neutral

Alaunos Therapeutics has higher earnings, but lower revenue than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	$3K	16,118.52	-$4.18M	-$2.13	N/A
Cocrystal Pharma	$225K	57.48	-$8.83M	-$0.73	N/A

Alaunos Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cocrystal Pharma's return on equity of -150.61% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cocrystal Pharma beats Alaunos Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Cocrystal Pharma compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Mereo BioPharma Group has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Mereo BioPharma Group presently has a consensus price target of $3.25, indicating a potential upside of 976.16%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, equities analysts plainly believe Mereo BioPharma Group is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cocrystal Pharma had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
Mereo BioPharma Group	Neutral
Cocrystal Pharma	Neutral

Cocrystal Pharma has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	96.41	-$41.88M	-$0.05	N/A
Cocrystal Pharma	$225K	57.48	-$8.83M	-$0.73	N/A

Mereo BioPharma Group's return on equity of -81.28% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Summary

Mereo BioPharma Group beats Cocrystal Pharma on 9 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Metagenomi currently has a consensus price target of $7.00, indicating a potential upside of 481.88%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts plainly believe Metagenomi is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Cocrystal Pharma	N/A	-150.61%	-97.86%

6.7% of Cocrystal Pharma shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cocrystal Pharma has lower revenue, but higher earnings than Metagenomi. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$22.33M	2.03	-$87.87M	-$2.30	N/A
Cocrystal Pharma	$225K	57.48	-$8.83M	-$0.73	N/A

In the previous week, Metagenomi had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Metagenomi and 1 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.00 beat Metagenomi's score of -0.28 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Metagenomi has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Summary

Metagenomi beats Cocrystal Pharma on 9 of the 17 factors compared between the two stocks.

How does Cocrystal Pharma compare to SCYNEXIS?

Cocrystal Pharma (NASDAQ:COCP) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Cocrystal Pharma has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
SCYNEXIS	-41.79%	-57.16%	-39.48%

In the previous week, Cocrystal Pharma had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for SCYNEXIS. Cocrystal Pharma's average media sentiment score of 0.00 equaled SCYNEXIS'saverage media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
SCYNEXIS	Neutral

6.7% of Cocrystal Pharma shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by insiders. Comparatively, 4.1% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

SCYNEXIS has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	$225K	57.48	-$8.83M	-$0.73	N/A
SCYNEXIS	$20.60M	1.95	-$8.61M	-$3.84	N/A

Cocrystal Pharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

SCYNEXIS has a consensus price target of $24.00, suggesting a potential upside of 492.45%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

SCYNEXIS beats Cocrystal Pharma on 9 of the 15 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.95M	$3.65B	$6.79B	$12.62B
Dividend Yield	N/A	2.18%	2.67%	9.67%
P/E Ratio	-1.29	21.42	26.95	24.00
Price / Sales	57.48	174.65	508.06	91.33
Price / Cash	N/A	150.24	49.71	59.37
Price / Book	2.04	8.03	10.60	6.18
Net Income	-$8.83M	$23.81M	$3.60B	$331.71M
7 Day Performance	-2.29%	-3.22%	-2.08%	-1.81%
1 Month Performance	-6.20%	-0.63%	0.21%	-2.35%
1 Year Performance	-41.38%	42.06%	22.79%	17.45%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	0.3593 of 5 stars	$0.94 +0.8%	N/A	-42.2%	$12.95M	$225K	N/A	10
MCRB Seres Therapeutics	2.7083 of 5 stars	$5.34 -5.0%	$17.00 +218.4%	-62.1%	$51.69M	$790K	N/A	330	High Trading Volume
TCRT Alaunos Therapeutics	0.211 of 5 stars	$2.09 +0.5%	N/A	-32.6%	$51.04M	N/A	N/A	40
MREO Mereo BioPharma Group	1.7658 of 5 stars	$0.31 -2.2%	$3.25 +935.0%	-82.1%	$50.12M	$500K	N/A	40
MGX Metagenomi	2.727 of 5 stars	$1.32 flat	$7.00 +430.3%	-43.8%	$49.70M	$25.21M	N/A	236	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. MCRB, TCRT, MREO, MGX, and SCYX

How does Cocrystal Pharma compare to Seres Therapeutics?

Summary

How does Cocrystal Pharma compare to Alaunos Therapeutics?

Summary

How does Cocrystal Pharma compare to Mereo BioPharma Group?

Summary

How does Cocrystal Pharma compare to Metagenomi?

Summary

How does Cocrystal Pharma compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. MCRB, TCRT, MREO, MGX, and SCYX

How does Cocrystal Pharma compare to Seres Therapeutics?

Which has more risk & volatility, COCP or MCRB?

Do analysts rate COCP or MCRB?

Is COCP or MCRB more profitable?

Do institutionals & insiders believe in COCP or MCRB?

Which has higher earnings and valuation, COCP or MCRB?

Does the media refer more to COCP or MCRB?

Summary

How does Cocrystal Pharma compare to Alaunos Therapeutics?

Does the media prefer TCRT or COCP?

Which has higher earnings & valuation, TCRT or COCP?

Which has more volatility & risk, TCRT or COCP?

Do insiders & institutionals hold more shares of TCRT or COCP?

Is TCRT or COCP more profitable?

Do analysts recommend TCRT or COCP?

Summary

How does Cocrystal Pharma compare to Mereo BioPharma Group?

Do institutionals & insiders believe in MREO or COCP?

Which has more volatility & risk, MREO or COCP?

Do analysts rate MREO or COCP?

Does the media refer more to MREO or COCP?

Which has preferable valuation and earnings, MREO or COCP?

Is MREO or COCP more profitable?

Summary

How does Cocrystal Pharma compare to Metagenomi?

Do analysts prefer MGX or COCP?

Is MGX or COCP more profitable?

Do institutionals and insiders have more ownership in MGX or COCP?

Which has better valuation & earnings, MGX or COCP?

Does the media favor MGX or COCP?

Which has more risk & volatility, MGX or COCP?

Summary

How does Cocrystal Pharma compare to SCYNEXIS?

Is COCP or SCYX more profitable?

Does the media prefer COCP or SCYX?

Do insiders and institutionals hold more shares of COCP or SCYX?

Which has better earnings and valuation, COCP or SCYX?

Which has more risk and volatility, COCP or SCYX?

Do analysts prefer COCP or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools